Changing the Future of Cancer Care
New research led by Kodai Abe, MD, PhD, has identified a promising molecular biomarker that may help researchers develop more personalized approaches to monitoring patients with intrahepatic cholangiocarcinoma (iCCA). This form of bile duct cancer can be difficult to treat and has a substantial risk of recurrence, making improved methods of identifying and monitoring disease an important area of research.
Working with investigators from Keio University in Tokyo, Japan, Dr. Abe and colleagues studied interleukin enhancer-binding factor 2 (ILF2), a protein involved in cellular responses to DNA damage. The researchers identified increased ILF2 activity in certain iCCA tumors and found associations with more aggressive disease and poorer clinical outcomes.
The team also found that ILF2 gene amplification could be detected in circulating cell-free DNA (cfDNA), fragments of genetic material released into the bloodstream from normal and cancer cells. These findings suggest that measuring ILF2 alterations in blood samples could potentially help assess recurrence risk after surgery and contribute to more individualized monitoring strategies.
Today, patients treated for intrahepatic cholangiocarcinoma typically require ongoing imaging and clinical follow-up to monitor for recurrence. A validated blood-based biomarker could eventually provide additional information about an individual’s risk and help physicians evaluate changes that may not be immediately apparent through conventional monitoring alone. However, the ILF2 approach remains investigational and requires further validation before clinical use.
We are incredibly proud of the dedication and collaboration that made this research possible. Discoveries like these bring us closer to a future where we can more precisely monitor patients after surgery, identify those at highest risk for recurrence, and develop more personalized treatment strategies that improve outcomes.
– Anton Bilchik, MD, FACS
The study also identified ILF2 and its relationship with the RNA helicase DHX9 as a potential area for therapeutic research. Investigating how these proteins influence DNA damage responses may help scientists understand vulnerabilities in certain cancer cells and explore whether disrupting these pathways could improve treatment sensitivity.
These findings do not establish ILF2-targeted treatment as an available therapy. Additional laboratory research and clinical studies will be needed to determine whether the identified mechanisms can lead to effective therapeutic or monitoring approaches.
“This study highlights the outstanding work being conducted by Dr. Abe and our translational research team to better understand the biology of aggressive cancers and identify opportunities to improve patient care,” said Dr. Anton Bilchik, Professor of Surgical Oncology, Chief of General Surgery, Director of the Gastrointestinal and Hepatobiliary Program, and Director of the Gastrointestinal Research Program at Saint John’s Cancer Institute and co-author of the study.
“This type of research demonstrates the power of connecting basic and translational discoveries with real-world clinical challenges,” said Dr. Matias A. Bustos, Head of Translational Research at Saint John’s Cancer Institute. “By identifying biomarkers that may help predict recurrence and guide treatment decisions, we are building the foundation for more personalized cancer care. As we continue to expand our laboratory and translational research capabilities, we are creating new opportunities to accelerate discoveries that can directly benefit patients and support the development of next-generation diagnostic and therapeutic approaches.”
Funding for this research was provided by the CORI Foundation and the Adelson Medical Research Foundation (AMRF).
Research Details
ILF2 Amplification and Molecular Monitoring in Intrahepatic Cholangiocarcinoma
The research examined the relationship between ILF2 amplification, cellular DNA damage responses, treatment sensitivity, and clinical outcomes in intrahepatic cholangiocarcinoma.
Laboratory analyses investigated how reducing ILF2 activity affected cancer cell survival and DNA damage. The researchers also examined the interaction between ILF2 and DHX9, an RNA helicase involved in regulating R-loops, structures that can form during gene transcription and contribute to genomic instability when not properly controlled.
Single-cell transcriptomic and copy-number analyses identified recurrent amplification of chromosome region 1q21.3 involving ILF2 in a subset of malignant cells. The investigators also detected ILF2 copy-number alterations in circulating cell-free DNA from patients before and after surgery.
In the reported clinical analysis, elevated postoperative ILF2 copy number was associated with increased recurrence risk and shorter recurrence-free survival. These findings support further investigation of ILF2 as a potential molecular marker for identifying patients who may require closer postoperative monitoring.
The laboratory results also raised questions about whether the ILF2–DHX9 pathway could influence sensitivity to DNA-damaging cancer treatments. This remains a research finding rather than an established therapeutic strategy.
Research Contributors
Kodai Abe, Kelly Chong, Yuta Abe, Minoru Kitago, Motonori Edanami, Yosuke Uematsu, Yohei Masugi, Akihisa Ueno, Yuko Kitagawa, Jason Mooney, Anton J. Bilchik, Matias A. Bustos, and Dave S. B. Hoon.
ASCO 2026 Research Abstract
ILF2 as a Predictor of Cisplatin Resistance and Clinical Outcomes in Intrahepatic Cholangiocarcinoma
The abstract describes recurrent ILF2 amplification, its relationship with DHX9 and DNA damage responses, and the potential clinical significance of circulating ILF2 copy-number measurements. The research also reports an association between postoperative ILF2 amplification and recurrence risk.
These findings require additional validation, and the proposed molecular monitoring and therapeutic applications remain investigational.
Read the Original ASCO 2026 Research Abstract
Research and the Future of Personalized Cancer Care
Understanding the biological characteristics of individual tumors is an important part of translational cancer research. Studies such as this one investigate how laboratory findings may eventually contribute to more precise methods of evaluating disease, identifying patients at increased risk, and selecting treatment strategies.
Although ILF2 testing is not yet established for routine postoperative monitoring of intrahepatic cholangiocarcinoma, the findings provide a foundation for further research into molecular surveillance and targeted therapeutic approaches.
Learn more about the Center for Gastrointestinal and Hepatobiliary Tumors and the ongoing research conducted at Saint John’s Cancer Institute.